BSP Pharmaceuticals
BSP Pharmaceuticals S.p. A. is focused on the development and manufacturing of anticancer drugs with high potency and cytotoxitc characteristics for the Pharmaceuticals Industry. BSP has been at the forefront in the fight against cancer since 2006. Innovation is the hallmark of BSP with investments in new technologies and production methods in a high containment plant.
Ajinomoto BioPharma Services
Ajinomoto Bio-Pharma Services offers comprehensive capabilities for small molecule APIs and biologics production, from process development and cGMP manufacturing to aseptic fill finish, including cytotoxics. As a global CDMO, they provide the adaptive solutions, responsive service, trusted partnership and peace of mind you’ve come to rely on.
Ambrx
Ambrx’s technology is designed to achieve the delivery of chemotherapy directly to a cancer cell by combining the advantages of highly specific cancer cell targeting mAbs securely linked or “conjugated” to a highly potent chemo payload. Using Ambrx’s proprietary protein engineering technology, this approach has the potential to eliminate the use of indiscriminate, non-targeted chemotherapy, which carries well-known side effects. Spun out of The Scripps Research Institute in 2003, Ambrx’s technology designed to prevent the premature release (i.e., into the bloodstream before binding to the cancer cell), of its cancer cell killing payload - a problem inherent to the use of other unstable conjugation technologies. With the competitive advantage of owning such protein engineering technology, Ambrx is advancing two antibody drug conjugates (ADCs) in focused clinical programs in prostate and breast cancer.
NJ Bio, Inc.
NJ Bio Inc. is a CRO that provides integrated chemistry and biology services to clients from the biotech and pharma sectors. Main service areas include antibody drug conjugates, nucleotide and oligonucleotide synthesis, multi-step organic synthesis, PROTAC and flow chemistry based process development.
MilliporeSigma
Millipore Sigma is the leading Life Science company, providing solutions as a strategic partner to help advance the promise of life-saving therapies. We have the largest offering of products for formulations, actives, and biotechnology processes.
Our joint ADC offering includes a full range of integrated contract manufacturing services for drug development and manufacturing that spans conjugation, mAbs, linkers, and payloads. To fit your ADC manufacturing needs, we offer a comprehensive processing portfolio from cell culture media to buffers, salts, and stabilizers and from chromatography to TFF equipment, including single-use templates.
Antibody-Drug Conjugate (ADC) Manufacturing.
Simris
Simris Alg is a biologics company, engaged in research, development and production of bioactive substances from cyanobacteria and microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. Their technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems.
Singzyme
Singzyme’s mission is to deliver on the promise of effective mmune-therapies by developing safer and more homogenous, precision medicines for the well-being of patients worldwide. Singzyme applies its platform technology in the field of mmune-therapies with a focus on the conjugation of active molecules to protein carriers, for example, but not limited to Antibody-Drug Conjugates (ADCs).
Synaffix
Synaffix BV is a biotech company that has established a proprietary, clinical-stage antibody-drug conjugate (ADC) technology platform that delivers best-in-class ADCs (safety and efficacy).
Through the platform, they can rapidly generate best-in-class ADCs for our partners from any antibody and our patent portfolio protects our proprietary processes and any resulting Products through at least 2039.